1
Mohamed SKIBA Mohamed SKIBA
SKIBA MOHAMED, BOUNOURE FREDERIC, MALLET ERIC: [fr] Composition pharmaceutique pour ladministration par voie nasale de la metopimazine, [de] Pharmazeutische Zusammensetzung zur nasalen Verabreichung von Metopimazine, [en] Pharmaceutical composition for nasal administration of metopimazine. SKIBA MOHAMED, April 17, 2013: EP2581085-A1 (1 worldwide citation)

[en] Composition comprises metopimazine or its salt, optionally a cyclodextrin and one or more excipients, where the composition is in the form of aqueous solution or powder. ACTIVITY : Antiemetic Gastrointestinal-Gen. Antiinflammatory Antidiarrheic. MECHANISM OF ACTION : None given.


2
Sanjay Kotha
Sanjay Kotha, Tirumalai S Sudarshan: Hemostatic composition. Materials Modification, Dinesh Agarwal P C, March 2, 2010: US07670623 (2 worldwide citation)

A hemostatic composition includes a carrier medium including a predetermined amount of a particulate material. The particulate material is comprised of core particles with a coating. The core particles have an average particle size of about 5 nm to 10 μm, and the coating is one of gold, silica, silv ...


3
Gary G Liversidge, Kenneth C Cundy, John F Bishop, David A Czekai: Surface modified drug nanoparticles. Sterling Drug, Arthur H Rosenstein, William J Davis, September 8, 1992: US05145684 (697 worldwide citation)

Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and dispersions conta ...


4
Abraham J Domb, Ruxandra Gref, Yoshiharu Minamitake, Maria Teresa Peracchia, Robert S Langer: Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers. Massachusetts Institute of Technology, Arnall Golden & Gregory, December 28, 1999: US06007845 (332 worldwide citation)

Particles are provided that are not rapidly cleared from the blood stream by the macrophages of the reticuloendothelial system, and that can be modified to achieve variable release rates or to target specific cells or organs. The particles have a core of a multiblock copolymer formed by covalently l ...


5
Justin Hanes, David A Edwards, Carmen Evora, Robert Langer: Particles incorporating surfactants for pulmonary drug delivery. Massachusetts Instite of Technology, The Penn State Research Foundation, Arnall Golden & Gregory, January 5, 1999: US05855913 (323 worldwide citation)

Aerodynamically light particles incorporating a surfactant on the surface thereof for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a ...


6
Stephen Brocchini, Stephen R Hanson, Joachim B Kohn: Polymeric drug formulations. Rutgers The State University of New Jersey, Synnestvedt & Lechner, March 2, 1999: US05877224 (304 worldwide citation)

Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug and a water-insoluble tissue-compa ...


7
Benjamin Oshlack, Mark Chasin: Orally administrable opioid formulations having extended duration of effect. Purdue Pharma, Davidson Davidson and Kappel, October 19, 1999: US05968551 (282 worldwide citation)

Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates includin ...


8
Gary G Liversidge, Elaine Liversidge, Pramod P Sarpotdar: Surface modified anticancer nanoparticles. Eastman Kodak Company, Arthur H Rosenstein, March 21, 1995: US05399363 (279 worldwide citation)

Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles exhibit reduced ...


9
Benjamin Oshlack, Frank Pedi Jr, Mark Chasin: Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer. Euroceltigue, Steinberg & Raskin, December 28, 1993: US05273760 (279 worldwide citation)

A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active agent with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature a ...


10
Benjamin Oshlack, Mark Chasin, Frank Pedi Jr: Controlled-release formulations coated with aqueous dispersions of ethylcellulose. Euroceltique, Steinberg Raskin & Davidson, December 5, 1995: US05472712 (270 worldwide citation)

A stabilized solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic polymer is obtained by overcoating a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic ...